NCT00153907已完成1 期
A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- To define the maximally tolerated dose and evaluate the feasibility and toxicity of capecitabine and oral navelbine administered in combination.
研究概览
简要总结
The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.
详细描述
- Not every patient will be receiving the same dose of capecitabine and navelbine. A small group will be enrolled onto the study and given certain doses of each drug. If they tolerate them well (have few or easily manageable side effects), the next small group of people enrolled will receive a higher dose of one of the drugs. This will continue until we find the highest doses of the drugs that can be given without causing serious or unmanageable side effects.
- Patients will be given oral navelbine on days 1 and 8 of each cycle, unless they are at the highest dose. In which case, they will be given navelbine on days 1, 8 and 15. Capecitabine will be given on days 1-14 of each cycle in two divided doses approximately 12 hours apart.
- While patients are on the study they will have the following tests and procedures performed: physical examination every 3 weeks; routine blood work every week; extensive laboratory tests every 3 weeks; disease status will be checked every 6 weeks (2 cycles) unless there are symptoms of disease progression.
- The weekly treatment will continue unless there is disease progression or unacceptable side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed breast cancer with evidence of locally advanced or metastatic disease
- •Female patients age 18 or older
- •No more than three prior chemotherapeutic regimens in the metastatic setting
- •ANC > 1,500/mm3
- •Platelet count > 100,000/mm3
- •SGOT < 3 x ULN
- •Bilirubin < 1.5 x ULN
- •Performance status of 0 or 1
- •At least 3 weeks since prior chemotherapy or 2 weeks since prior radiation, surgery or any anticancer investigational agent
- •Able to swallow and retain oral medications
- •Measurable disease
排除标准
- •Prior vinca alkaloids
- •Active gastrointestinal disease or disorder
- •Pregnant or lactating
- •Serious co-morbid medical or psychological condition
- •Prior bone marrow or stem cell transplant
- •Prior documented severe sensitivity to 5-FU
结局指标
主要结局
To define the maximally tolerated dose and evaluate the feasibility and toxicity of capecitabine and oral navelbine administered in combination.
时间窗: 2 years
次要结局
未报告次要终点
研究者
Craig A. Bunnell, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute
研究点 (4)
Loading locations...
相似试验
已完成
1 期
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + DasatinibSolid TumorMetastatic Colorectal CancerNCT00920868Herbert Hurwitz, MD22
已完成
1 期
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast CancerHormone Receptor-positive Breast CancerNCT05064085H. Lee Moffitt Cancer Center and Research Institute13
已完成
1 期
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal CancerColorectal NeoplasmsNCT00291486Ludwig Institute for Cancer Research19
已完成
1 期
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00702182National Cancer Centre, Singapore30
进行中（未招募）
不适用
Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinomfortgeschrittenes kolorektalen Karzinom mit inoperablen MetastasenMedDRA version: 9.1Level: LLTClassification code 10010035Term: Colorectal cancer stage IVEUCTR2007-000233-18-DEniversität zu Köln